COMP <GO>
REGN vs UNH // NET PROFIT MARGIN
Regeneron Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: REGN 6
— UNH 9
▲ NET PROFIT MARGIN LEADER: REGN
LAST: $927.89 (+13.33%) • MKT CAP: $84.30B
net-margins
31.40%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
net-margins
3.14%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (REGN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | REGN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 11.47% | -2.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.2x | 16.4x | +3.75 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.14% | 6.48% | -1.34 | UNH | /fcf-yield <GO> |
| Operating Margin | 24.90% | 4.82% | +20.08 | REGN | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 31.40% | 3.14% | +28.26 | REGN | /net-margins <GO> |
| Revenue Growth (YoY) | 1.00% | 6.46% | -5.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 2.28% | -1.84 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.72 | 3.12 | +4.60 | REGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | REGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.74% | +0.66 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 79.1 | 56.0 | +23.06 | REGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 0.33 | +0.83 | REGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 17.1x | +0.31 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $84.30B | $364.66B | -$280.36B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | REGN REV | UNH REV | REGN GROSS % | UNH GROSS % | REGN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.34B | $447.57B | 44.0% | 88.7% | $4.33B | $16.07B |
| FY 2024 | $14.20B | $400.28B | 44.0% | 88.3% | $3.78B | $20.70B |
| FY 2023 | $13.12B | $371.62B | 44.0% | 89.6% | $4.00B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
REGN // BETA 1.16
UNH // BETA 0.33